CD99L2

Across TCGA pan-cancer cohorts, CD99L2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CD99L2 data layer compared with 22 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher CD99L2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CD99L2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

UCEC, PDAC, and LUAD are the cancer types where CD99L2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Quartile	II,III,IV	0.299	0.812	.016	10	view →
PDAC	OS	Tertile	IV	0.973	0.443	.024	9	view →
LUAD	DFS	Tertile	All	1.000	0.767	.036	1	view →
HNSC	DFS	Quartile	III,IV	0.908	0.694	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CD99L2–UCEC (DFS)

Open the UCEC breakdown →